Arrowhead Research Corp (ARWR) Drops 7.16% on January 25

Equities Staff |

Arrowhead Research Corp (ARWR) was one of the Russell 2000's biggest losers for Monday January 25 as the stock slid 7.16% to $3.89, a loss of $-0.3 per share. Starting at an opening price of $4.16 a share, the stock traded between $3.89 and $4.25 over the course of the trading day. Volume was 765,108 shares over 3,101 trades, against an average daily volume of 1.6 million shares and a total float of 59.55 million.

The losses send Arrowhead Research Corp down to a market cap of $231.67 million. In the last year, Arrowhead Research Corp has traded between $9.36 and $3.26, and its 50-day SMA is currently $5.58 and 200-day SMA is $6.14.

Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.

Arrowhead Research Corp is based out of Pasedena, CA and has some 104 employees. Its CEO is Christopher Anzalone.

For a complete fundamental analysis analysis of Arrowhead Research Corp, check out Equities.com’s Stock Valuation Analysis report for ARWR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

THC Therapeutics Inc

THC Therapeutics Inc is a health and healing company in the cannabis industry. The Company is engaged in developing dHydronator which is used to reduce moisture and effectively dry out…

Private Markets

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…